Omniscan is a drug owned by Ge Healthcare. It is protected by 1 US drug patent filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 01, 2013. Details of Omniscan's patents and their expiration are given in the table below.
Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
---|---|---|---|
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
US5560903 | Method of enhancing paramagnetism in chelates for MRI |
Oct, 2013
(11 years ago) |
Expired
|
US patents provide insights into the exclusivity only within the United States, but Omniscan is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Omniscan's family patents as well as insights into ongoing legal events on those patents.
Omniscan's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Omniscan's generic launch date based on the expiry of its last outstanding patent is estimated to be Oct 01, 2013 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Omniscan Generics:
There are no approved generic versions for Omniscan as of now.
About Omniscan
Omniscan is a drug owned by Ge Healthcare. Omniscan uses Gadodiamide as an active ingredient. Omniscan was launched by Ge Healthcare in 1993.
Approval Date:
Omniscan was approved by FDA for market use on 08 January, 1993.
Active Ingredient:
Omniscan uses Gadodiamide as the active ingredient. Check out other Drugs and Companies using Gadodiamide ingredient
Dosage:
Omniscan is available in injectable form for injection use. Given below is detailed information on Dosage -
Strength | Dosage Form | Availability | Application Pathway |
---|---|---|---|
287MG/ML | INJECTABLE | Prescription | INJECTION |
14.35GM/50ML (287MG/ML) | INJECTABLE | Discontinued | INJECTION |
28.7GM/100ML (287MG/ML) | INJECTABLE | Discontinued | INJECTION |